These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 28366593)

  • 1. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
    Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
    J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.
    Olry de Labry Lima A; Gimeno Ballester V; Sierra Sánchez JF; Matas Hoces A; González-Outón J; Alegre Del Rey EJ
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1027-1035. PubMed ID: 29937273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
    Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
    Robinson JG; Jayanna MB; Brown AS; Aspry K; Orringer C; Gill EA; Goldberg A; Jones LK; Maki K; Dixon DL; Saseen JJ; Soffer D
    J Clin Lipidol; 2019; 13(4):525-537. PubMed ID: 31281070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
    Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
    Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.
    Borissov B; Urbich M; Georgieva B; Tsenov S; Villa G
    J Mark Access Health Policy; 2017; 5(1):1412753. PubMed ID: 29321830
    [No Abstract]   [Full Text] [Related]  

  • 19. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population.
    Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A
    Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.